Literature DB >> 23543868

Drug Resistant Breast Cancer Cell Line Displays Cancer Stem Cell Phenotype and Responds Sensitively to Epigenetic Drug SAHA.

Shan Lu1, Vinod Labhasetwar.   

Abstract

Cancer stem cell (CSC) population in solid human breast tumor was identified by CD44(+)/CD24(-) phenotype, characterized by high tumorigenicity, invasiveness and drug resistance. In this study, we characterized drug resistant breast cancer cell line-MCF-7/Adr and a number of breast cancer cell lines using flow cytometry, immunofluorescence, mammosphere formation assay and migration assay, examining their CSC immunophenotypes, presence of CSC proteins, tumorigenicity in vitro and migratory rates, respectively. Our results show that MCF-7/Adr cells uniformly display CSC characteristics yet retain low migratory rate. They are also able to self-renew and differentiate under floating culture conditions. Furthermore, MCF-7/Adr is selectively sensitive to epigenetic drug, suberoylanilide hydroxamic acid (SAHA), losing drug resistance and changes morphology yet retaining CSC immunophenotypes. In conclusion, we show that resistant breast cancer cell line MCF-7/Adr demonstrates uniform CSC like characteristics and are sensitive to epigenetic drug treatment.

Entities:  

Keywords:  Breast Cancer Stem Cell; Cancer Therapy; Drug Resistance; Epigenetic Therapy; Epithelial Mesenchymal Transition; Surface Markers

Year:  2012        PMID: 23543868      PMCID: PMC3608528          DOI: 10.1007/s13346-012-0113-z

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  32 in total

1.  Stem cells: Self-renewal writ in blood.

Authors:  John E Dick
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

2.  Breast cancer stem cells revealed.

Authors:  John E Dick
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-25       Impact factor: 11.205

3.  CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis.

Authors:  Petra Baumann; Natascha Cremers; Frans Kroese; Gertraud Orend; Ruth Chiquet-Ehrismann; Toshi Uede; Hideo Yagita; Jonathan P Sleeman
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

4.  The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation.

Authors:  Tiffany M Phillips; William H McBride; Frank Pajonk
Journal:  J Natl Cancer Inst       Date:  2006-12-20       Impact factor: 13.506

5.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

Review 6.  Clonogenic cells in acute myeloblastic leukemia.

Authors:  J D Griffin; B Löwenberg
Journal:  Blood       Date:  1986-12       Impact factor: 22.113

7.  Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

Authors:  Kazutoshi Takahashi; Shinya Yamanaka
Journal:  Cell       Date:  2006-08-10       Impact factor: 41.582

8.  Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.

Authors:  Benny K Abraham; Peter Fritz; Monika McClellan; Petra Hauptvogel; Maria Athelogou; Hiltrud Brauch
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

9.  EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy.

Authors:  Walid A Osta; Yian Chen; Kaidi Mikhitarian; Michael Mitas; Mohamed Salem; Yusuf A Hannun; David J Cole; William E Gillanders
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

10.  Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture, 1982).

Authors:  E A McCulloch
Journal:  Blood       Date:  1983-07       Impact factor: 22.113

View more
  8 in total

Review 1.  Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles.

Authors:  Chiranjeevi Peetla; Sivakumar Vijayaraghavalu; Vinod Labhasetwar
Journal:  Adv Drug Deliv Rev       Date:  2013-09-19       Impact factor: 15.470

Review 2.  Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.

Authors:  Silvia Schmidtova; Katarina Kalavska; Lucia Kucerova
Journal:  Curr Oncol Rep       Date:  2018-09-26       Impact factor: 5.075

Review 3.  Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.

Authors:  Rui Xue Zhang; Ho Lun Wong; Hui Yi Xue; June Young Eoh; Xiao Yu Wu
Journal:  J Control Release       Date:  2016-06-08       Impact factor: 9.776

Review 4.  The crossroads between cancer stem cells and aging.

Authors:  Sara Santos Franco; Hadas Raveh-Amit; Julianna Kobolák; Mohammed H Alqahtani; Ali Mobasheri; András Dinnyes
Journal:  BMC Cancer       Date:  2015-01-15       Impact factor: 4.430

Review 5.  Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal.

Authors:  Fabrizio Marcucci; Cristiano Rumio; François Lefoulon
Journal:  Front Oncol       Date:  2016-05-10       Impact factor: 6.244

Review 6.  In vitro models of cancer stem cells and clinical applications.

Authors:  Sara S Franco; Karolina Szczesna; Maria S Iliou; Mohammed Al-Qahtani; Ali Mobasheri; Julianna Kobolák; András Dinnyés
Journal:  BMC Cancer       Date:  2016-09-30       Impact factor: 4.430

7.  CD44 Promotes Migration and Invasion of Docetaxel-Resistant Prostate Cancer Cells Likely via Induction of Hippo-Yap Signaling.

Authors:  Chih-Jen Lai; Ching-Yu Lin; Wen-Ying Liao; Tzyh-Chyuan Hour; Horng-Dar Wang; Chih-Pin Chuu
Journal:  Cells       Date:  2019-03-30       Impact factor: 6.600

8.  Targeting Tumorigenicity of Breast Cancer Stem Cells Using SAHA/Wnt-b Catenin Antagonist Loaded Onto Protein Corona of Gold Nanoparticles.

Authors:  Azam Shamsian; Mohammad Reza Sepand; Marziye Javaheri Kachousangi; Tahereh Dara; Seyed Nasser Ostad; Fatemeh Atyabi; Mohammad Hossein Ghahremani
Journal:  Int J Nanomedicine       Date:  2020-06-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.